The Preventive Effects of Lactobacillus casei on Acute Lung Injury Induced by Lipopolysaccharide

Abstract

Lactobacillus has been reported to inhibit acute lung injury (ALI). However, the molecular mechanism of Lactobacillus casei ( L. casei ) in preventing ALI has not been identified, so we investigated whether L. casei pretreatment could inhibit the activation of TLR4/MyD88/NF-κB signaling pathway following ALI. ALI model was established by intraperitoneal injection of 2 mg/kg lipopolysaccharide (LPS) to female BALB/c mice. In L. casei LC2W group, mice were intragastrically administrated L. casei LC2W for a week, before the ALI modeling. The serum of normal BALB/c mice after intragastric administration of L. casei LC2W was used for in vitro cell assays. The serum was pre-incubated with mouse macrophage cell line (RAW264.7) and human lung cell line (HLF-A), then LPS was added to co-incubate. Compared with ALI model group, L. casei LC2W pretreatment significantly reduced lung pathological damage, the number of neutrophils and total cells in bronchoalveolar lavage fluid. Besides, L. casei LC2W pretreatment could significantly reverse the abnormal expression of ICAM-1, IL-6, TNF-α and IL-10 in lung tissue and serum, plus, L. casei LC2W significantly reduced the phosphorylation levels of IRAK-1 and NF-κB p65. In vitro, the serum decreased the up-regulation of IL-6 and TNF-α in cell lines induced by LPS. In conclusion, L. casei LC2W intragastric administration pretreatment could significantly improve LPS-induced ALI in mice, probably through circulation to reach the lungs so as to inhibit the inflammatory response induced by activation of TLR4/MyD88/NF-κB signaling pathway.

A systematic review and meta-analyses of interleukin-1 receptor associated kinase 3 (IRAK3) action on inflammation in in vivo models for the study of sepsis

“…Of the 49 included in vivo studies, 12 studies reported data from experiments performed using in vivo human model [ 45 , 50 – 60 ], 34 studies [ 29 , 32 , 36 – 41 , 43 , 61 – 85 ] used rodents (mice or rats), and the remaining three used sheep [ 44 ], cows [ 86 ] or pigs [ 42 ]. All included human studies (12 studies) used LPS administration with in vivo doses of 2–4 ng/kg.…”

“… In one-challenge intervention, mice or rats were injected with or inhaled LPS [ 37 , 61 , 62 , 66 , 70 , 72 – 77 , 80 , 85 ], or were intranasally inoculated with S. pneumoniae [ 41 ], or intraperitoneally inoculated with E . coli [ 79 ], or underwent CLP [ 82 ].…”

Lactobacillus rhamnosus Restores Antiviral Signaling and Attenuates Cytokines Secretion from Human Bronchial Epithelial Cells Exposed to Cigarette Smoke and Infected with SARS-CoV-2

“…In this concern, new anti-inflammatory therapies as probiotics have deserved highlights due to beneficial effect on lung diseases, such as asthma, ARDS, COPD, and pneumonia [50][51][52][53]. Even in that preliminary, the present study shows that Lr restores the antiviral signaling and reduces Regarding the choice of the probiotic Lactobacillus rhamnosus (Lr) to carry out the experimental assays of the present study, this decision was made based on results published by our group that describe the beneficial effect of Lr on cell signaling of the lung inflammatory response and the airway remodeling observed in murine models of COPD and ARDS [54,55].…”